A safety study evaluating non-COVID-19 mortality risk following COVID-19 vaccination

[1]  M. Netea,et al.  Beneficial non-specific effects of live vaccines against COVID-19 and other unrelated infections , 2022, The Lancet Infectious Diseases.

[2]  J. Sándor,et al.  Effectiveness of COVID-19 Vaccination in Preventing All-Cause Mortality among Adults during the Third Wave of the Epidemic in Hungary: Nationwide Retrospective Cohort Study , 2022, Vaccines.

[3]  Michael John Smith,et al.  Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. , 2022, JAMA.

[4]  P. Monach,et al.  Impact of prior SARS-CoV-2 infection on incidence of hospitalization and adverse events following mRNA SARS-CoV-2 vaccination: A nationwide, retrospective cohort study , 2022, Vaccine.

[5]  H. Sørensen,et al.  SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study , 2021, BMJ.

[6]  Stanley Xu,et al.  Guillain-Barre Syndrome after COVID-19 Vaccination in the Vaccine Safety Datalink , 2021, medRxiv.

[7]  J. Glanz,et al.  COVID-19 Vaccination and Non–COVID-19 Mortality Risk — Seven Integrated Health Care Organizations, United States, December 14, 2020–July 31, 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[8]  E. Woo,et al.  Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barré Syndrome, February-July 2021. , 2021, JAMA.

[9]  R. Balicer,et al.  Myocarditis after Covid-19 Vaccination in a Large Health Care Organization , 2021, The New England journal of medicine.

[10]  J. Nelson,et al.  Surveillance for Adverse Events After COVID-19 mRNA Vaccination. , 2021, JAMA.

[11]  V. Mor,et al.  Adverse events following mRNA SARS-CoV-2 vaccination among U.S. nursing home residents , 2021, Vaccine.

[12]  B. Long,et al.  Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines , 2021, The American Journal of Emergency Medicine.

[13]  J. Gargano,et al.  The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[14]  J. Gargano,et al.  The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Moderna COVID-19 Vaccine — United States, December 2020 , 2021, MMWR. Morbidity and mortality weekly report.

[15]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[16]  J. Gargano,et al.  The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine — United States, December 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[17]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[18]  W. Miao,et al.  A Selective Review of Negative Control Methods in Epidemiology , 2020, Current Epidemiology Reports.

[19]  Sophia R. Newcomer,et al.  Order of Live and Inactivated Vaccines and Risk of Non–vaccine-targeted Infections in US Children 11–23 Months of Age , 2020, The Pediatric infectious disease journal.

[20]  Kenneth Rockwood,et al.  Measuring Frailty in Medicare Data: Development and Validation of a Claims-Based Frailty Index , 2018, The journals of gerontology. Series A, Biological sciences and medical sciences.

[21]  E. Horváth-Puhó,et al.  Conditioning on future exposure to define study cohorts can induce bias: the case of low-dose acetylsalicylic acid and risk of major bleeding , 2017, Clinical epidemiology.

[22]  J. Mcnicholl,et al.  Risk of Nontargeted Infectious Disease Hospitalizations Among US Children Following Inactivated and Live Vaccines, 2005–2014 , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  Robert Platt,et al.  Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. , 2016, Journal of clinical epidemiology.

[24]  M. Schumacher,et al.  Multiple time scales in modeling the incidence of infections acquired in intensive care units , 2016, BMC Medical Research Methodology.

[25]  M. Daley,et al.  Vaccination and 30-Day Mortality Risk in Children, Adolescents, and Young Adults , 2016, Pediatrics.

[26]  S. Jacobsen,et al.  Demographic characteristics of members of the Vaccine Safety Datalink (VSD): A comparison with the United States population. , 2015, Vaccine.

[27]  S. Omer,et al.  Mortality rates and cause-of-death patterns in a vaccinated population. , 2013, American journal of preventive medicine.

[28]  Samy Suissa,et al.  Metformin and the Risk of Cancer , 2012, Diabetes Care.

[29]  M. Lipsitch,et al.  Negative Controls: A Tool for Detecting Confounding and Bias in Observational Studies , 2010, Epidemiology.

[30]  M. Raebel,et al.  Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[31]  P. Austin.  Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples , 2009, Statistics in medicine.

[32]  Heather J Whitaker,et al.  Case series analysis for censored, perturbed, or curtailed post-event exposures. , 2008, Biostatistics.

[33]  Cecile Viboud,et al.  Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. , 2007, The Lancet. Infectious diseases.

[34]  J. Nelson,et al.  Evidence of bias in estimates of influenza vaccine effectiveness in seniors. , 2006, International journal of epidemiology.

[35]  B. Psaty,et al.  Functional status is a confounder of the association of influenza vaccine and risk of all cause mortality in seniors. , 2006, International journal of epidemiology.

[36]  Cecile Viboud,et al.  Impact of influenza vaccination on seasonal mortality in the US elderly population. , 2005, Archives of internal medicine.

[37]  J. Robins,et al.  Marginal Structural Models and Causal Inference in Epidemiology , 2000, Epidemiology.

[38]  G. Imbens.  The Role of the Propensity Score in Estimating Dose-Response Functions , 1999 .

[39]  Niels Keiding,et al.  Statistical Models Based on Counting Processes , 1993 .

[40]  D. Rubin,et al.  Reducing Bias in Observational Studies Using Subclassification on the Propensity Score , 1984 .

[41]  D. Rubin,et al.  The central role of the propensity score in observational studies for causal effects , 1983 .

[42]  R. Prentice,et al.  Commentary on Andersen and Gill's "Cox's Regression Model for Counting Processes: A Large Sample Study" , 1982 .